# US 2021/0340167 A1 · Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340167 A1
- Document ID: US20210340167A1
- Status: Published application
- Kind: A1
- Application number: 17/372,125
- Filed: 2021-07-09
- Published: 2021-11-04
- Earliest claimed: 2018-07-06
- Assignees: Kancera AB
- Applicants: Kancera AB
- Inventors: Jan VÅGBERG; Styrbjörn BYSTRÖM; Elisabeth OLSSON; Mattias JÖNSSON
- Web page: https://patentgrep.com/patent/US20210340167A1

## CPC

- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided a compound of formula I, wherein R1, R2, Q1 and are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.

## Claims

### Claim 1

A compound (2R)-2-[(2-Amino-5-{[(1S)-1-phenylethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound as claimed in claim 1, wherein the pharmaceutically acceptable salt is a base addition salt.

### Claim 3 (depends on 1)

The compound as claimed in claim 1, wherein the pharmaceutically acceptable salt is an ammonium salt or an alkali metal salt.

### Claim 4 (depends on 1)

The compound as claimed in claim 1, wherein the compound is in the form of a base addition salt.

### Claim 5 (depends on 1)

The compound as claimed in claim 1, wherein the compound is in the form of an ammonium salt or an alkali metal salt.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a compound as defined in claim 1, including pharmaceutically acceptable salts thereof, in admixture with one or more pharmaceutically acceptable excipient.

### Claim 7 (depends on 6)

The pharmaceutical composition as claimed in claim 6, wherein the composition further comprises water and less than 20% (w/w) solubilising excipients.

### Claim 8 (depends on 7)

The pharmaceutical composition as claimed in claim 7, wherein the composition is in the form of an aqueous solution.

### Claim 9 (depends on 6)

The pharmaceutical composition as claimed in claim 6, wherein the composition is in the form of a powder.

### Claim 10 (depends on 1)

A method of treating and/or preventing a disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 comprising administering to a patient in need thereof, a therapeutically effective amount of a compound as defined in claim 1, including pharmaceutically-acceptable salts thereof, wherein the disease or disorder is selected from the group consisting of acute and/or chronic inflammation, a cardiovascular disease, an autoimmune disease, a gastrointestinal disease and pain.

### Claim 11 (depends on 10)

The method as claimed in claim 10, wherein the disease or disorder is arteriosclerosis.

### Claim 12 (depends on 10)

The method as claimed in claim 10, wherein the disease or disorder is myocardial infarction.

### Claim 13 (depends on 10)

The method as claimed in claim 10, wherein the disease or disorder is multiple sclerosis.

### Claim 14 (depends on 10)

The method as claimed in claim 10, wherein the disease or disorder is pancreatitis.

### Claim 15 (depends on 10)

The method as claimed in claim 10, wherein the disease or disorder is chemotherapy-induced pain.

### Claim 16 (depends on 10)

The method as claimed in claim 10, wherein the disease or disorder is neuropathic pain.

### Claim 17 (depends on 1)

A combination product comprising:
(I) a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof; and
(II) one or more other therapeutic agent that is useful in the treatment and/or prevention of a disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1, wherein the disease or disorder is selected from acute and/or chronic inflammation, a cardiovascular disease, an autoimmune disease, a gastrointestinal disease and pain,
wherein each of components (1) and (II) is formulated in admixture, optionally with a pharmaceutically-acceptable excipient.
